Latest News

Second Mucodis® Medical Device Launch

Second Mucodis® Medical Device Launch

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce the launch of Mucodis® mouthwash by Colonis, part of its Niche Pharmaceuticals division. Mucodis® mouthwash is the fifth regulated product to be launched by Colonis and the second in a range of Mucodis® branded medical devices to treat some of the side effects of cancer treatments in patients.

The mouthwash has been developed to prevent oral mucositis, one of the most common and debilitating complications of chemotherapy and radiation. Mucositis can lead to several problems including pain, nutritional problems resulting from the inability to eat, and increased risk of infection due to open sores in the lining of the mouth. It has a significant effect on the patient's quality of life and can affect the patient's ability to continue with chemotherapy as prescribed.1 Severe cases will usually require hospital treatment for monitoring and nutritional support.2

The launch of this mouthwash complements the earlier launch of Mucodis® Oromucosal Spray in November 2015. The spray is indicated for the treatment of oral mucositis in specific patients after the condition has developed. However, the mouthwash has an indication for the prevention of oral mucositis in patients as they start cancer treatment, enabling its use in a larger population.

Quantum has a specific therapeutic account team in place to support the launch of the Mucodis® range. In discussions with oncology specialists, nurses and pharmacists, a clear medical need amongst patients has been identified for this range of products. Due to this anticipated demand, as with the Mucodis® Oromucosal Spray, the entire first manufacturing batch of Mucodis® mouthwash has been bought by pharmaceutical wholesalers.

It is anticipated that further Mucodis® products will be launched during the financial year ended 31 January 2017.

Andrew Scaife, CEO of Quantum Pharma, commented: "Mucodis® mouthwash is an important addition to the Mucodis® range, not only for Quantum as we establish the Niche Pharmaceutical division in the UK, but for patients undergoing treatment for cancer. We believe the outlook for the Mucodis® range is very positive and we are delighted to be able to offer multi-faceted relief from the commonly experienced side-effects of cancer treatment."


Posted by: Quantum Webmaster on 25th January 2016